Skip to content
Spin & Win — Health-and-wellness — Fitness-and-exercise — Symphony's Worldwide Headlines

New Wave Biotech and iMEAN Team Up to Revolutionize Biomanufacturing Efficiency

What if biomanufacturers could predict—and eliminate—costly production flaws before they happen? This game-changing collaboration makes it possible. Early adopters report 8.6x yield improvements and 92% fewer experiments needed.

,   and  Administrator
2 min read
The image shows a diagram of the chemical biology process, with diagrams and text written on a...
The image shows a diagram of the chemical biology process, with diagrams and text written on a white background. At the top left corner of the image, there is a graph depicting the relationship between bioorganic and biochemistry.

New Wave Biotech and iMEAN Team Up to Revolutionize Biomanufacturing Efficiency

A new partnership between New Wave Biotech and iMEAN aims to cut costs and improve efficiency in biomanufacturing. The collaboration targets a long-standing issue: the disconnect between early-stage design and later production steps. This gap often leads to high downstream expenses, which can make up 50–80% of total manufacturing costs. The two companies have combined their technologies to create an end-to-end solution for bioprocess optimisation. This covers everything from designing organisms to purifying the final product. Their integrated system also includes cost and sustainability assessments, helping manufacturers make better-informed decisions early on.

iMEAN specialises in metabolic modelling, using genome-scale reconstructions and kinetic pathway analysis. Their tools have already saved clients over €600,000 in research and development costs within six months. In one case, a client saw production increase by 2.8 times after applying iMEAN’s optimisation methods. New Wave Biotech brings its Bioprocess Foresight platform to the partnership. This technology optimises downstream processing across 16 different unit operations, incorporating economic and environmental impact analyses. Previous users of the platform have reported an 8.6-fold improvement in yields and a 55% reduction in unit costs. They also required 92% fewer experiments to achieve optimal conditions. The partnership allows companies to simulate entire bioprocesses digitally before committing to real-world production. By linking upstream and downstream modelling, manufacturers can now anticipate and avoid costly downstream issues early in the design phase. This approach addresses a persistent challenge in large-scale production of bio-based products and novel foods, where strain design and media optimisation often clash with purification and extraction requirements.

The combined offering enables manufacturers to screen, simulate, and refine bioprocesses more effectively. Early results from both companies suggest significant savings in time, cost, and experimental effort. The goal is to streamline production from the initial design stage through to final purification.

Read also:

Related

Latest